These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
163 related items for PubMed ID: 21155966
1. Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A. Rea CJ, Foley JH, Ingerslev J, Sørensen B. J Thromb Haemost; 2011 Mar; 9(3):510-6. PubMed ID: 21155966 [Abstract] [Full Text] [Related]
2. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking. Beckman JD, Holle LA, Wolberg AS. J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382 [Abstract] [Full Text] [Related]
3. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. Sørensen B, Ingerslev J. J Thromb Haemost; 2004 Jan; 2(1):102-10. PubMed ID: 14717973 [Abstract] [Full Text] [Related]
4. An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A. Rea CJ, Foley JH, Bevan DH, Sørensen B. Ann Hematol; 2014 Apr; 93(4):683-92. PubMed ID: 24193375 [Abstract] [Full Text] [Related]
9. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone. Tomokiyo K, Nakatomi Y, Araki T, Teshima K, Nakano H, Nakagaki T, Miyamoto S, Funatsu A, Iwanaga S. Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255 [Abstract] [Full Text] [Related]
13. Concizumab improves clot formation in hemophilia A under flow. Jewell MP, Ashour Z, Baird CH, Manco Johnson M, Warren BB, Wufsus AR, Pallini C, Dockal M, Kjalke M, Neeves KB. J Thromb Haemost; 2024 Sep; 22(9):2438-2448. PubMed ID: 38815755 [Abstract] [Full Text] [Related]
14. FXIII: mechanisms of action in the treatment of hemophilia A. Rea CJ, Foley JH, Okaisabor O, Sørensen B. J Thromb Haemost; 2014 Feb; 12(2):159-68. PubMed ID: 24354581 [Abstract] [Full Text] [Related]
15. Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation. Li R, Panckeri KA, Fogarty PF, Cuker A, Diamond SL. Haemophilia; 2017 Sep; 23(5):759-768. PubMed ID: 28475272 [Abstract] [Full Text] [Related]
16. Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays. Brophy DF, Martin EJ, Barrett JC, Nolte ME, Kuhn JG, Hedner U, Ezban M. Blood Coagul Fibrinolysis; 2011 Sep; 22(6):541-6. PubMed ID: 21681082 [Abstract] [Full Text] [Related]
17. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Gerotziafas GT, Chakroun T, Depasse F, Arzoglou P, Samama MM, Elalamy I. Thromb Haemost; 2004 May; 91(5):977-85. PubMed ID: 15116259 [Abstract] [Full Text] [Related]
20. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Allen GA, Persson E, Campbell RA, Ezban M, Hedner U, Wolberg AS. Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):683-9. PubMed ID: 17204663 [Abstract] [Full Text] [Related] Page: [Next] [New Search]